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Adverse drug reactions (ADRs) are the unintended side effects of drugs. They are cate-
gorised as either predictable or unpredictable drug-induced injury and may be exhibited
after a single or prolonged exposure to one or multiple compounds. Historically, toxicol-
ogy studies rely heavily on animal models to understand and characterise the toxicity of
novel compounds. However, animal models are imperfect proxies for human toxicity and
there have been several high-proﬁle cases of failure of animal models to predict human
toxicity e.g. ﬁaluridine, TGN1412 which highlight the need for improved predictive models
of human toxicity. As a result, stem cell-derived models are under investigation as poten-
tial models for toxicity during early stages of drug development. Stem cells retain the
genotype of the individual from which they were derived, offering the opportunity to
model the reproducibility of rare phenotypes in vitro. Differentiated 2D stem cell cultures
have been investigated as models of hepato- and cardiotoxicity. However, insufﬁcient
maturity, particularly in the case of hepatocyte-like cells, means that their widespread use
is not currently a feasible method to tackle the complex issues of off-target and often
unpredictable toxicity of novel compounds. This review discusses the current state of the
art for modelling clinically relevant toxicities, e.g. cardio- and hepatotoxicity, alongside
the emerging need for modelling gastrointestinal toxicity and seeks to address whether
stem cell technologies are a potential solution to increase the accuracy of ADR predictivity
in humans.
Introduction
Adverse drug reactions (ADRs) are the harmful side effects of medicine which may occur after acute
or chronic exposure to a compound. They place a signiﬁcant ﬁnancial burden on the healthcare indus-
try and contribute to ∼5% of all hospital admissions [1]. Similarly, ADRs are burdensome to pharma,
who face ﬁnancial loss due to drug withdrawal if toxicity is detected post-marketing. The current cost
of developing a drug is $648 million USD over 10–15 years [2], which is a major concern given that
many drugs do not exhibit ADRs until late-stage trials when large investments of time and money
have already been made. Between 1980 and 2009, 15% of licenced drugs having proven efﬁcacious in
phase II trials were terminated with the main reasons being unanticipated cardiotoxicity, hepatotox-
icity and gastrointestinal (GI) toxicity [3]. Currently, cardiac drug-induced injury is the leading cause
of drug withdrawal, whilst drug-induced liver injury is the second leading cause of drug termination
and causes ∼50% of acute liver failure [4]. Unpredicted cardiotoxicity is the main reason for drug ter-
mination, accounting for 28% of drug withdrawals [5]. In the U.S.A., the GI tract has been associated
with 20% of drug-induced events [6].
Human embryonic stem cells (hESCs) were initially discovered in blastocyst stage embryos, whereas
induced pluripotent stem cells (iPSCs) were developed approximately 13 years ago, by reprogramming
adult somatic cells by overexpression of the Yamanaka factors: Oct4, Sox2, Klf4 and cMyc (OSKM)
[7]. Both hESCs and iPSCs are pluripotent, meaning that they can differentiate into any somatic cell
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type. IPSCs can be derived from individuals known to have unusual or diseased phenotypes, these phenotypes
can then be introduced into in vitro assays at early stages during toxicity testing. Genetic modiﬁcation
platforms such as CRISPR-Cas9 can be utilised to generate isogenic human iPSC lines that can be used to
assess cross-organ ADR responses from the same patient. The process for deriving iPSCs is minimally invasive
requiring only a skin biopsy or blood sample, though any tissue type can be used.
Stem cells are able to be exploited in both 2D and 3D, therefore, utilising spheroids and organoids to model
in vivo systems. Spheroids are self-aggregating clusters of cells that form spontaneously when adherent cells are
denied an attachment surface. Spheroids have been observed for almost as long as cell culture has been prac-
ticed with observations of cells ‘rounding off into little spheres’ as early as 1907 [8]. Due to their 3D physi-
ology, spheroids can be used to replicate a 3D microenvironment which is thought to improve the relevance of
cell models to organ parenchyma. Despite their advantages over monolayer systems, spheroids are not perfect
as they are typically hypoxic above a given size due to the diffusion gradient of oxygen through non-
vascularised tissue, which often leads to necrosis in the core. Despite hypoxia being observed in spheroids,
most 2D and 3D cultures are said to be in hyperoxic conditions (21% O2), which causes hepatocyte
de-differentiation and therefore a loss of speciﬁc cell functions. Notably, 5% O2 is very effective in maintaining
epithelial morphology and retain hepatic functions for up to 5 days [9]. Due to their necrotic core, spheroids
can be alternatively used to model small tumour growth, as angiogenesis has not yet occurred in vivo and
accurately models an oxygen gradient in a tumour microenvironment. Generally, spheroids are comprised of a
single cell/tumour cell type. Whilst spheroids are useful in modelling 3D culture, due to their necrotic core and
lack of vasculature, spheroids can be used to model tumour growth. Whilst in vitro cultures are not entirely
representative of normal tissue, mixed populations of non-transformed cells are possible, as is layering with
multiple cell types to recapitulate organ structure. Crucially, spheroids do not spontaneously form organotypic
structures or differentiate into more mature tissues.
Organoids are a 3D heterogeneous collection of cells, self-organising to recreate organ microanatomy.
Organoids self-arrange with a central lumen, allowing for more complete drug penetration and the establish-
ment of a toxicological gradient. Organoids are often derived from tissue-resident stem cells, thus making
biopsy of the target tissue necessary. This has several disadvantages compared with iPSC-derived models,
which can be derived from easily accessible cells [10], including collection time, patient consent and the
volume of culture material. However, organoids remain a promising nascent model for examining toxicity in
multiple tissue types. Moreover, some studies have shown that organoids may be produced from iPSCs and
exhibit the phenotype of the patient overcoming this limitation of organoid culture [11]. A study conducted by
the Clevers group has demonstrated that hepatic organoids express a similar level of CYP3A4 compared with
freshly isolated hepatocytes and was veriﬁed via midazolam metabolism. This study highlighted the potential of
hepatic organoids, replicating a clinical level of metabolism, whilst adopting key 3D functions to mimic an in
vivo system [12].
Hepatotoxicity
The liver is the major site of metabolism and detoxiﬁcation of xenobiotic compounds, which leads to high inci-
dences of ADRs, therefore, hepatoxicity is a leading cause of attrition in drug development. Human primary
hepatocytes (hPH) are considered the gold standard for studying in vitro hepatotoxicity though they are not a
ﬂawless model. A major limitation of using mature hPH is that they rapidly de-differentiate immediately after
the tissue is removed from the patient’s blood supply and continue to de-differentiate over approximately
1-week post-isolation in culture [13]. Moreover, de-differentiation causes a large reduction in expression of key
hepatic proteins, e.g. cytochromes P450 and other key phase I/II enzymes and transporters, which directly
affect drug metabolism and therefore the validity of the cell model.
To overcome the limitations of hPH stability in vitro, a more physiologically relevant and stable model is
required to measure the long-term effects of drug-induced toxicity. Immortalised cell lines, such as HepG2 and
HepaRG cells can be used, primarily due to their highly proliferative nature and ease of culture. However, these
cell lines are far less physiologically relevant compared with hPHs often lacking many key hepatic proteins.
iPSC-derived hepatocyte-like cells (iPSC-HLCs) are a potential ‘Goldilocks’ model combining the replicative
nature of cell lines with the potential for close physiological relevance offered by primary cells. They are also
able to maintain the phenotype of a single donor allowing repeat experiments under similar genetic conditions,
something that is typically not possible with primary cells. Despite their promise, iPSC-HLCs do not currently
fully recapitulate the phenotype of freshly isolated hPHs, and, like hPH, do not proliferate when differentiated.
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However, only a few phenotypic markers are used, which suggests an inadequate benchmark for hepatocyte
phenotyping [3].
The phenotype of hepatic models can be examined using drugs previously known to be metabolised by spe-
ciﬁc enzymes. Several key drugs were analysed, namely, phenacetin (CYP1A2), diclofenac (CYP2C9), omepra-
zole (CYP2C19), metoprolol (CYP2D6) and midazolam (CYP3A4) [14]. HepaRG and iPSC-HLCs displayed
similar metabolic rates after 8 days, except in the case of CYP3A4-dependent metabolism, where iPSC-HLCs
showed substantially higher metabolism (Table 1). The iPSC-HLCs demonstrated stable metabolic rates of all
tested cytochromes P450 until day 29, except for CYP3A4 which showed a sharp decrease to levels similar to
those observed in HepaRG cells at day 9 (Table 1).
IPSC-HLCs have shown early success in safety assessments, particularly with regard to their ability to repro-
ducibly model diseased phenotypes. High-throughput screening is widely applied in drug development to pri-
oritise lead molecules, to decrease animal use [15], allowing for Tox21/ToxCast programmes to aid
decision-making [16] during drug discovery. The necessity to generate data on the potential toxicity of at least
30,000 compounds, is expected to require up to 10 million animals [17]. In one study, iPSCs were derived from
patients with α1antitrypsin (A1AT) deﬁciency [18], and through high-throughput screening, a compound that
signiﬁcantly reduced defective A1AT within the cytoplasm was identiﬁed [19]. As a result, iPSCs from diseased
donors are being investigated for other conditions, including hypercholesterolaemia [20], glycogen storage
disease [20–23], Gaucher’s disease [24], hereditary tyrosinaemia [20], hereditary cholestasis [18] and defective
mitochondrial respiratory chain complex disorder [23].
Human skin-derived precursors (hSKP) are a multipotent stem cell line that can be differentiated towards a
hepatic fate (hSKP-HPC). The response of hSKP-HPC to paracetamol (APAP) was recently examined using
qPCR analysis [25]. Notably, CYP3A5, a foetal isoform of CYP3A4, demonstrated a 15-fold increase in
hSKP-HPC upon APAP exposure demonstrating the capacity for induction of key metabolic enzymes in these
cells [20]. Basal levels of several CYPs in hSKP-HPC have been found to be minimal [26], however, it has been
hypothesised that the CYP expression may ﬂuctuate depending on the xenobiotic to which they are exposed.
Like most cells, stem cells are currently most commonly cultured in 2D conditions. This is a major limitation
since these models cannot completely mimic the physiology of an in vivo system e.g. no connective tissue or
the presence of extracellular matrix. 2D systems have contributed to a poor standard of pre-clinical in vitro
hepatotoxicity assays. Consequently, more than 90% of drugs that yield positive data during in vitro pre-clinical
studies fail the safety margins required in subsequent clinical trials. As a result of a lack of key phenotypic
properties in 2D models, 3D models are currently being explored to improve the reliability of in vitro toxicity
assays [26].
HepG2 cells in a typical rigid 3D culture show improved hepatic functions over monolayer cultures in terms
of glycogen storage, bile salt transportation, development of bile canaliculi and increased expression of
CYP3A4, CYP2E1, CYP2C9, CYP2C19, CYP2D6 and UGT1A1 [26]. Drug-induced cholestasis (DIC) is mea-
sured in vitro by the compound’s ability to inhibit bile salt export pump (BSEP), however, DIC is typically
complex, multifactorial and delayed in its manifestation [27–29], and therefore innovative toxicity models are
required. Spheroid models formed via hPH and HepaRG cells were dosed with cholestatic-inducing compound
chlorpromazine [30]. Both models displayed DIC related toxicity, whilst the HepaRG spheroid also displayed
Table 1 Enzyme metabolic rates, depending on the concentration of product produced, comparing
immortalised HepaRG cells against iPSC-Hep cell lines [14], showing the different systems
responding to a known compound over 8 and 29 days. IPSCs responded in a far more stable manner
over 29 days, as HepaRG cells metabolic rates were too low to measure
Cell model Day Cell per well
Drug oxidation activity
pmol products/hour/1 × 105 cells
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4
HepaRG 8 1.8 0.93 ± 0.03 0.040 ± 0.004 4.1 ± 1.0 11 ± 2.0 20 ± 2.0
iPSC #1 8 1.5 0.93 ± 0.24 0.004 ± 0.001 1.2 ± 0.20 7.0 ± 2.0 94 ± 20.0
29 1.1 1.2 ± 0.10 0.053 ± 0.006 7.9 ± 0.80 24 ± 4.0 26 ± 2.0
iPSC #2 8 1.5 0.78 ± 0.19 0.002 ± 0.0004 1.0 ± 0.10 4.4 ± 1.1 77 ± 6.0
29 1.3 1.2 ± 0.10 0.027 ± 0.005 6.5 ± 0.70 16 ± 1.0 24 ± 3.0
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reduced F-actin expression, indicating chlorpromazine in disrupting structural integrity, which has been impli-
cated in early chlorpromazine-induced cholestasis through oxidative stress [31].
Organoid models are being developed in the hope that they will improve upon current 3D models. When
compared with human foetal liver progenitor cell-derived hepatocytes (hFLPC-HLCs) human liver organoids
showed far greater urea and albumin production. After 21 days human liver organoids produced ∼4.4-fold
higher albumin concentrations and 4.0-fold higher urea concentrations than hFLPC-HLCs. These results show
that organoids are potentially capable of greater physiological relevance than traditional 2D culture systems
[32]. It has been suggested that isolated primary hepatocytes can be used to generate branched hepatocyte-like
organoids (Hep-Org), when exposed to a variety of small molecules, including RSPO-1 and other Wnt agonists
[33]. Through biliary ductal cell isolation, it is possible to generate cholangiocyte-like organoids (Chol-Org),
which differ greatly from Hep-Org, as shown through RNA analysis, and through lineage tracing, loosely indi-
cates a similarity between primary hepatocytes and Hep-Org, however, Hep-Orgs have shown decreased
HNF4a and albumin expression, 2- and 4-fold decrease, respectively, whilst Chol-Orgs demonstrated
>1000-fold decrease [33]. Notably, genes involved in hepatocyte functions such as cytochrome P450 activity,
glycogen metabolism, lipid metabolism, steroid metabolism, urea cycle and complement activation all displayed
very similar expression proﬁles between Hep-Orgs and primary hepatocytes [33].
Cardiotoxicity
IPSC-derived cardiomyocytes (iPSC-CMs) have great potential in cardiotoxicity research. They offer an attract-
ive platform to mimic cardiovascular diseases, model early stages of cardiac development and advance predict-
ive toxicology assays in vitro. Like other iPSC-derived models, iPSC-CMs retain the donor phenotype
potentially allowing multiple experiments on rare phenotypes and have been used to model complex channelo-
pathies such as prolonged QT syndrome, catecholaminergic polymorphic ventricular tachycardia and familial
hypertrophic cardiomyopathy (HCM) [34–36], alongside those seen in Table 2. The predictive capability of
iPSC-CMs is therefore dependent on key structural characteristics and electrophysiology in vitro.
A key beneﬁt to using iPSC-CMs is phenotypic retention, which is the ability to model drug-induced cardio-
toxicity in diseased states. Cardiomyocytes were dosed with 1–300 nM of cisapride, a potent HERG channel
blocker, using control human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and hESC-CMs from
long QT syndrome (LQT), HCM and dilated cardiomyopathy (DCM) patient-derived cardiomyocytes
(Table 2). Cisapride was observed to provoke early after depolarisation (EAD) at different concentrations for
each diseased cell type [37]. Nicorandil, a K+ channel opener, was next applied to elicit drug-induced responses
in disease cell models. Nicorandil has been implicated in shortening the QT interval through increased K+
efﬂux, therefore inducing arrhythmias [38–40]. Upon Nicorandil application to diseased cardiomyocytes,
100 nM was found to both normalise APD prolongation and remove spontaneously occurring EADs. Many
studies also reported arrhythmia induction in patients receiving high levels of Nicorandil due to excessive
QT shortening [41–43]. Several key disease phenotypes have also been modelled (Table 2), with successful
toxicology studies performed.
In a recent study, hESC-CMs were exposed to a range of cadmium chloride (CdCl2) concentrations to
induce morphological changes. Consistent with previous studies, signiﬁcantly higher levels of reactive oxygen
species (ROS) were observed in CdCl2 treated cells compared with control [44–46]. In addition, hESC-CMs
Table 2 Cardiac diseases which have been modelled in vitro using iPSC-CMs.
Many drugs have been tested using disease state iPSC-CMs
Disease Tested drug(s)
LQT1 Propranolol [77], isoprenaline [78]
LQT2 Nifedipine [38], propranolol [79], allele-specific siRNA [80], cisapride [81]
LQT8 Roscovitine [39]
CPTV1 Isoprenaline, forskolin [35]
DCM Metoprolol, norepinephrine [82]
HCM Propranolol, verapamil, nifedipine [36]
ARVC Nifedipine [83], isoproterenol [84]
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displayed sarcomeric disorganisation and disruption, increased nucleoplasmic ratio and nuclear membrane
shrinkage [47]. These results are in concordance with in vivo studies, in which CdCl2 disrupts cardiac structure
and integrity. These results show that hESC-CMs can recapitulate complex cardiac structure and electrophysi-
ology, which is important for accurate prediction of cardiotoxicity.
A critical function of cardiomyocytes is their contractile ability, therefore, the effects of E-4031 (a class III
antiarrhythmic compound) was considered to examine antiarrhythmic effects. Administration of E-4031 at
30–100 nM, resulted in a signiﬁcant decrease in beating rate (32.7 ± 1.2/min) versus vehicle control and a
decrease in contractile velocity versus vehicle control [48]. The recent work of the Wu group is an important
advance as it shows that even for a complex, off-target toxicity such as doxorubicin-induced cardiotoxicity,
which likely entails decreased mitochondrial function, perturbed calcium regulation and oxidative stress, it is
possible to emulate this using patient-derived single cell iPSC-CMs [49]. A critical function of cardiomyocytes
is their contractile ability, therefore, the antiarrhythmic effects of E-4031(a class III antiarrhythmic compound)
were examined. Administration of E-4031 signiﬁcantly decreased contractile velocity and beating rate in
iPSC-CTs (32.7 ± 1.2/min) [48]. Dose-dependent doxorubicin toxicity has been successfully modelled in
iPSC-CTs, reporting the reported minimum effective concentration of doxorubicin in monolayer iPSC-CM
systems is not signiﬁcantly different from the concentrations achieved in pre-clinical studies, therefore, indicat-
ing a comparable tolerance to cytotoxins between systems [48,50–52].
A recent study treated cardiomyocyte spheroids with antibiotic, antidiabetic and anti-cancer drugs [52]. The
spheroids physiologically showed relevant structure and metabolic functions, as 6/8 known cardiotoxic com-
pounds tested were also detected in vitro, therefore, CM spheroids correctly identiﬁed 75% of cardiotoxic com-
pounds, compared with clinical data. The study has found 3D cardiac tissue models tested in this manner are
more sensitive to cardiotoxicity than traditional viability assays. Another recent study has reported that rosiglita-
zone; a potent antidiabetic drug, induced severe contractile failures in mice at 10–30 mM [53], when
iPSC-CM-derived spheroids were treated in a similar manner, the microtissue stopped contracting at 50 mM. This
study suggests that spheroids are not currently as sensitive as an in vivo model, and whilst they are not a perfect
model, they can exhibit physiological changes in response to an insult. Spheroids exhibit action potential propaga-
tion, force transduction and contractile tension, which play a critical role in pharmacologically induced responses
of cardiomyocytes and show increased expression of cardiac troponin (cTnT) and aMHC [54–56].
There are, however, shortcomings with iPSC-CMs which must be overcome to establish a reliable in vitro
model. The maturity of iPSC-CMs must be improved to establish predictive electrical, mechanical and meta-
bolic function. Stem cell differentiation protocols can lead to variability, depending on the protocol used. This
can lead to differences in phenotype and variation in the proportion of cell types produced, e.g. atrial-like cells
or pacemaker-like cells. A common problem with 3D cardiomyocytes is the extracellular matrix affecting the
contraction and relaxation of the system which may restrict the ability to contract due to the attachment to a
rigid matrix. To negate the effect of a matrix upon 3D-CMs, it is possible to generate ‘free-ﬂoating’ spheroid
like structures, e.g. hanging droplet formation, which displays beating cardiomyocytes.
Gastrointestinal toxicity
The GI tract plays an important role in xenobiotic bioactivation, metabolism and detoxiﬁcation, as it is enriched
with xenobiotic processing proteins. The epithelium of the GI tract has a rapid cell turnover, involving the prolif-
eration of stem cells at the base of the crypt which produces daughter cells that then migrate along the crypt–
villus axis. Intestinal stem cells either divide asymmetrically, which leads to one identical daughter stem cell and
one transit amplifying cell that initially retains some proliferative capacity, but eventually becomes a committed
progenitor. Rarely, stem cells divide symmetrically giving rise to two stem cells. The Wnt target gene
leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5) [57] is expressed in cells found at the base of
a crypt and is widely believed to label active cycling stem cells. Lineage tracing using LGR5 has shown that all
ﬁve differentiated intestinal epithelial cells arise from these stem cells: columnar epithelium (mainly absorptive
enterocytes), goblet cells, Paneth cells, tuft cells and neuroendocrine cells [58]. LGR5 positive cells are located at
the base of small intestinal and colonic crypts in crypt base columnar cells, which are thought to be active adult
intestinal stem cells [11] and self-renew with an ∼24-h cell cycle time [59]. Therefore, LGR5 detection would
allow for efﬁcient characterisation of adult stem cells in vitro. Whilst adult stem cells are source-limited in com-
parison with iPSC enteroids, they enable spontaneous formation of organoid structures, maintaining any genetic
mutations to model disease states. Also, tissue-derived organoids can be generated more cheaply and with greater
efﬁciency than iPSC enteroids, since differentiation is not required.
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GI organoids are well established, characterised and have a relatable metabolic proﬁle compared with donor
matched tissue [58]. GI organoids are generated via stem cell isolation from the intestinal crypt [60]. Crypt cul-
tures form spherical structures almost immediately, with small buds appearing typically after 5 days [11].
Human-derived GI organoids require a culture in differentiation medium to generate all mature cell lineages
[61] and there are subtle differences in growth medium and dynamics between small intestinal-derived enter-
oids and colon-derived colonoids [62]. Multiple phase I/II drug-metabolising enzymes and transporters have
been identiﬁed in enteroids [10]. Stable crypt cultures express high levels of CES1/2, UTG1A1 and key drug
transporters ABCC2 and ABCB1A [63].
Irinotecan is a potent anti-cancer drug, which upon hydrolysation by carboxylesterases (CES) forms the active
topoisomerase inhibitor SN-38, which undergoes glucuronidation by UGT1A1 to form SN-38G. Cytochrome
P450 3A4 (CYP3A4), is one of the most versatile drug-metabolising enzymes, accounting for the metabolism of
approximately half of all prescribed medications [64] and is responsible for hepatic metabolism of irinotecan.
Typically, the bioactivation and detoxiﬁcation of SN-38 have been accredited to hepatic pathways [63] through
CYP3A4 metabolism, though CYP3A4 is also present in the GI tract. However, recent studies using GI organoids
have implicated intestinal CES2 with a greater afﬁnity for irinotecan metabolism than hepatic CES1 [59]. GI orga-
noid mediated irinotecan metabolism can be measured via intra-/extracellular concentrations of irinotecan/
SN-38/SN-38G and can be used to quantify bioactivation and detoxiﬁcation using HPLC-MS analysis [65].
Further metabolic studies have shown that the presence of metabolites was detected in the extracellular medium,
rising in concordance with irinotecan concentration. Intracellular SN-38 was signiﬁcantly higher than SN-38G,
which suggests signiﬁcant efﬂux of SN-38G. GI organoids derived from UGT1A1 knockdown mice retained their
genotype and did not express UGT1A1, as a result, SN-38G was not detected [65].
Intestinal organoids can replicate typical transport physiology, alongside host–pathogen interactions.
Therefore, human intestinal organoids (HIO) can be employed as a model to understand salt/water transport
and diarrhoea-related pathophysiology. Human GI organoids have been shown to express sodium and chloride
transporters (NHE3 and DRA respectively), chloride efﬂux channels (CFTR and BLM NCKCC1), sodium/
potassium-ATPase and potassium channels [66].
GI organoids are a useful model to create disease states in vitro, allowing for genetic and pathogenic inﬂuences
to be analysed. Activation of cAMP signalling increases the membrane potential in wild type but not CFTR−/−
murine organoids [67], upon treatment with forskolin, apical ﬂuid secretion is observed, leading to intestinal cell
shrinkage and organoid expansion allowing for a useful model to monitor intestinal CFTR-related ﬂuid secretion
[67,68], which has enabled the development of a pre-clinical screening assay to assess how patients respond to
expensive cystic ﬁbrosis drugs [69]. Diarrhoea, cholera, rotavirus and enterohaemorrhagic Escherichia coli (EHEC)
are amongst the major causes of death worldwide [70]. Both cholera and rotavirus inhibit NHE3, by causing the
GPCR to remain in an active state, leading to an increase in intracellular cyclic AMP which continually activates
the CFTR [71]. Previous studies have also used iPSC-derived organoids in studying rotaviral infection [72]. HIO
treated with a calcium/calmodulin kinase 2 inhibitor (STO-609) have been found to have signiﬁcantly lower rota-
virus infection, quantiﬁed by infectious virus particle production [66]. EHEC infection results in GI damage
leading to micropinocytosis induction [72] which is indicative of symptoms found in vivo. IPSC-derived HIO
exposed to a known antigen known to induce an identical response to EHEC, undergo large cytoskeletal changes,
resembling micropinocytosis, highlighting the utility of GI organoids as an in vitro model [67].
Human colonic organoids, isolated from healthy and adenocarcinoma tissue have been used to screen com-
pounds, to establish their effect on patients with different genomes. Adenocarcinomic organoids derived from
patients that exhibited a loss-of-function mutation in TP53 showed resistance to MDM2 inhibitor nutlin-3a, whilst
‘healthy’ organoids showed cell death. This has been further demonstrated when organoids from colonic tumours
expressing KRAS mutations, exhibited a resistance to cetuximab (anti-EGFR inhibitor) [73]. Through genome
sequence analysis, performed on organoids derived from a patient diagnosed with gastric cancer and metastasis,
the presence of TFGBR2 was identiﬁed as a genetic factor for increased risk of metastasis [74]. Utilising
CRISPR-Cas9, colorectal organoids can be effective in pre-clinical drug screening assays. In a KRAS wild-type
colon tumouroid cell line that was sensitive to combinational therapy (EGFR and MEK inhibitors), the introduc-
tion of a KRASG12D mutation via CRISPR resulted in a loss of drug sensitivity. As the genetic makeup of these iso-
genic lines can be said to be identical before genome editing, this ﬁnding proved that it was indeed the RAS status
of the tumour that was responsible for the loss of drug sensitivity. Therefore, CRISPR-guided genetic modiﬁcation
of organoids can serve to strengthen conclusions based on large drug screens [75], however, this technology is best
served once the mechanism behind the disease is known. Modiﬁed isogenic cells provide little information in
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detecting ADRs that were not detected in humans during pre-clinical testing. Isogenic cells can, however, provide
a very useful resource upon conﬁrming a genetic disposition towards ADRs.
Conclusion
Patient-derived iPSC/hESCs can play a role in drug discovery and pre-clinical toxicity testing for the treatment
of patients with GI, cardiovascular and liver diseases. Current drug testing platforms, such as animal studies
and human clinical trials are not comprehensive, therefore, human iPSCs may provide an advantage which can
enhance the current approaches to drug toxicology studies. Moreover, the ability of human iPSCs to simulate
organ systems in vitro may allow studying the effects of drug metabolites on various cell types. Many studies
have utilised iPSC-based systems, in both 2D and 3D, to identify potential ADRs through disease modelling,
metabolism studies and proteomic studies. Due to the phenotypic retention of iPSCs, the efﬁciency of differen-
tiation and epigenetic shadowing, disease states can be modelled, allowing for patient-speciﬁc in vitro analysis.
Whilst the application of iPSCs in toxicity testing and drug development represents a very advanced and prac-
tical use of stem cells, the acceptance and incorporation of the pharmaceutical industry to implement a new
approach to current methods will be a slow process [76]. Whilst iPSC-derived hepatocytes are a valuable
resource, they are not yet considered to be a ‘perfect’ mature hepatocyte, which may limit their use in vitro,
despite their many advantages: cost-effectiveness, an unlimited source of hepatocytes, and the potential of high-
throughput screening.
Organoids are another promising model for in vitro toxicity, currently there are several issues preventing
their widespread use. Organoids are fragile in culture since they rely on a gel-like scaffold of BME-2 or
Matrigel to grow, limiting their scale-up efforts. Another concern is that the organoid culture methodology is
currently under patent, which may potentially limit their availability to be used commercially. With the current
technology available, it is unlikely iPSC/hESC-derived systems and patient-derived organoids are ready to
replace animal models, this is mainly due to the complexity of recreating an in vivo system where every tissue
is represented. Organoids cannot recreate a fully vascularised system and incorporate multiple cell types, e.g.
macrophages and ﬁbroblasts. In the future, we hope the ﬁeld can advance in such a manner that allows for the
co-culture of organoids with other cell types whilst retaining a physiologically relevant structure. The ﬂaws
listed however are synonymous amongst most in vitro systems and not exclusive to stem cell systems. In con-
clusion, no current system can be said to be perfect, but due to the advantages and ﬂexibility of stem cell
systems, in both 2D and 3D, they are likely to be very useful to model toxicity in vitro, and in the future will
feature more prominently in toxicity studies. In this review, we have discussed how stem cell models as in vitro
pre-clinical assays are rapidly evolving. These systems are sensitive to speciﬁc genome modiﬁcation and the
assessment of a patient’s susceptibility to a drug before clinical exposure. The rapid advancement of these
systems to accurately predict patient response, particularly in the liver, heart and GI systems, will greatly accel-
erate the advancement of drugs from their development to clinical use, as these organs express the greatest
abundance of key drug-metabolising enzymes and consequently show the greatest susceptibility to ADRs.
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